Tyler Z. Gillingham

Tyler Z. Gillingham

Auto-generated profile, based on publicly available information

Tyler Z. Gillingham

Picower Institute for Learning and Memory, Massachusetts Institute of Technology 1 Department of Brain and Cognitive Sciences Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
WRWilliam T. Ralvenius
William T. Ralvenius
AMAlison E. Mungenast
Alison E. Mungenast
HWHannah Woolf
Hannah Woolf
MHMargaret M. Huston
Margaret M. Huston
TGTyler Z. Gillingham
Tyler Z. Gillingham
LTLi-Huei Tsai
Li-Huei Tsai
Pervasive neuroinflammation occurs in many neurodegenerative diseases, including Alzheimer’s disease (AD). SPI1/PU.1 is a transcription factor located at a genome-wide significant AD-risk locus and its reduced expression is associated with delayed onset of AD. We analyzed single-cell transcriptomic datasets from microglia of human AD patients and found an enrichment of PU.1-binding motifs in the differentially expressed genes. In hippocampal tissues from transgenic mice with neurodegeneration, we found vastly increased genomic PU.1 binding. We then screened for PU.1 inhibitors using a PU.1 reporter cell line and discovered A11, a molecule with anti-inflammatory efficacy and nanomolar potency. A11 regulated genes putatively by recruiting a repressive complex containing MECP2, HDAC1, SIN3A, and DNMT3A to PU.1 motifs, thus representing a novel mechanism and class of molecules. In mouse models of AD, A11 ameliorated neuroinflammation, loss of neuronal integrity, AD pathology, and improved cognitive performance. This study uncovers a novel class of anti-inflammatory molecules with therapeutic potential for neurodegenerative disorders.